ArticleClinical kidney journal2015
Plasma exchange for paediatric kidney disease-indications and outcomes: a single-centre experience.
Article in Clinical kidney journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Therapeutic Plasma Exchange in Pediatric Care: Insights from a Tertiary Care Centre Experience.Indian pediatrics · 2026Article
- Key technical aspects and vascular access safety in membrane-based therapeutic plasma exchange for the pediatric population.Archives of medical science : AMS · 2026Article
- Safety and Efficacy of Therapeutic Plasma Exchange in Pediatric Non-Neurological Diseases.International journal of nephrology and renovascular disease · 2026Article
- Scope, Safety, and Feasibility of Therapeutic Plasma Exchange in Pediatric Intensive Care Unit: A Single-center Experience.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2023Article
- Centrifugal Therapeutic Plasma Exchange in Pediatric Patients.Indian journal of pediatrics · 2021Article
- Therapeutic plasma exchange: single-center experience in children with kidney disorders.Pediatric nephrology (Berlin, Germany) · 2021Article
- Therapeutic Plasma Exchange Using Membrane Plasma Separation.Clinical journal of the American Society of Nephrology : CJASN · 2020Review
- Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances.Clinical kidney journal · 2015Article
- Patient outcome in antibody-positive systemic vasculitis treated with therapeutic plasma exchange.Asian journal of transfusion scienceArticle
- Therapeutic plasma exchange for pediatric nonrenal disease indications and outcomes: A single-center experience.Asian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOutcome data in paediatrics regarding the use of plasmapheresis for immunological kidney disease are scarce.
objectivesWe aimed to evaluate the role of plasmapheresis in children presenting with severe renal impairment secondary to immunological kidney diseases.
methodsA retrospective chart review of children admitted between January 2009 and August 2013 to the Paediatric Nephrology Unit, Christian Medical College, Vellore, India, and requiring plasma exchange was undertaken. Demographic and clinical data were studied and descriptive statistics applied for analysis.
resultsSixteen children underwent plasmapheresis with a male:female ratio of 10:6 and a mean age of 10.2 years (range 5-15 years). Twelve children had atypical haemolytic uraemic syndrome, two had anti-glomerular basement disease and one each had lupus nephritis with neurological manifestation and anti-nuclear cytoplasmic antibody-associated vasculitis. The mean serum creatinine at presentation was 6.52 [interquartile range (IQR) 4.96-7.85] mg/dL with a mean eGFR of 43 (IQR 27.54-56.7) mL/min/1.73 m(2). Other presenting features included nephrotic range proteinuria (69%), gross haematuria (27%), hypertension (94%) and seizures (37.5%). All children received 1.5 times plasma volume plasmapheresis (mean 11 sessions, range 5-26), dialysis and immunosuppressive therapy. The mean duration of follow-up was 4 months (range 2-24 months) with a majority of the children (15/16, 93.75%) surviving acute illness. One child died of overwhelming sepsis and another was lost to follow-up. Of the survivors, eight had eGFR >60 mL/min/1.73 m(2), while eGFR was 15-60 mL/min/1.73 m(2) in the remaining six children. Eight children were still requiring antihypertensive medications and two were continuing peritoneal dialysis at the last follow-up. Thus early introduction of plasmapheresis along with other supportive therapy in immunological kidney disease may improve outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.